Fabrazyme IV 5mg, containing Agalsidase beta (genetically recombinant), is manufactured by Sanofi. This injectable drug, with YJ code 3959409D1029 and standard 5mg x 1 bottle, is an enzyme replacement therapy used in the treatment of Fabry disease.
Fabrazyme IV 5mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).